{'fraction_non_alphanumeric': 0.032474804031354984, 'fraction_numerical': 0.019036954087346025, 'mean_word_length': 5.385714285714286, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
BRAF (V600E) mutation analysis on liquid‐based cytology‐processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma

Activating mutations in the valine‐to‐glutamic acid substitution at position 600 of the v‐raf murine sarcoma viral oncogene homolog B1 (BRAF‐1) gene are detected frequently in patients with papillary thyroid carcinoma (PTC). These mutations have been identified in approximately 29% to 69% of PTCs and in >80% of PTCs of the tall cell variant, whereas they have not been detected in benign lesions or in the majority of those (80%) with the follicular variant of PTC. The objective of the current study was to evaluate the role of liquid‐based cytology (LBC) for the detection of BRAF mutations in the outcome of patients who have thyroid PTC measuring ≤1 cm and, hence, in guiding their clinical and surgical management.